肿瘤坏死因子抑制剂治疗类风湿关节炎:随机对照试验与常规临床实践中的疗效与效果
该研究基于芬兰国家生物制剂治疗登记队列,观察2004至2014年间启动TNF抑制剂治疗的类风湿关节炎患者的真实世界效果,并与27项随机对照试验的纳入标准进行比对。结果显示,6个月时EULAR中等和良好反应率分别为69%和40%,DAS28缓解率为47%,仅7.6%–44%的患者可能符合随机对照试验纳入标准,且符合标准者治疗反应更优。结论认为随机对照试验中评估的TNF抑制剂疗效不能直接外推至芬兰常规医疗。
要点
- 真实世界6个月EULAR中等/良好反应率69%/40%,DAS28缓解率47%。
- 仅7.6%–44%患者可能符合27项随机对照试验纳入标准。
- 符合随机对照试验标准者治疗反应优于不符合者,MTX联用影响显著。
核心结论
- 仅小部分真实世界患者符合随机对照试验纳入标准,随机对照试验中TNF抑制剂疗效不能直接外推至芬兰常规医疗。
研究设计与样本
- 基于芬兰国家生物制剂治疗登记(纵向观察性队列)识别2004–2014年启动TNF抑制剂治疗的类风湿关节炎患者,并将基线特征与27项随机对照试验纳入标准比对。
主要发现
- 首个TNF抑制剂治疗6个月时EULAR中等和良好反应率分别为69%和40%。
- ACR20、ACR50、ACR70反应率分别为48%、27%和13%,DAS28缓解率为47%。
- 仅7.6%–44%的患者可能符合随机对照试验纳入标准,符合者治疗反应优于不符合者。
- 不同TNF抑制剂大多等效,但MTX联用对治疗反应有重大影响。
关键数值与推荐
- EULAR中等反应率69%、良好反应率40%(首个TNF抑制剂治疗6个月)。
- ACR20/50/70反应率分别为48%、27%、13%,DAS28缓解率47%。
- 仅7.6%–44%患者可能符合27项随机对照试验纳入标准。
临床怎么用
- 解读随机对照试验中TNF抑制剂疗效时需考虑真实世界患者常不符合严格纳入标准。
- 真实世界中应重视MTX联用以优化TNF抑制剂治疗反应。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Efficacy of TNF inhibitors in the treatment of RA assessed in randomized controlled trials (RCTs) may not be fully comparable to routine care owing to the stringent inclusion criteria. The objective of this study was to observe the effectiveness of TNF inhibitors in real-world patients and assess the patients' potential eligibility for the RCTs. METHODS: RA patients starting a TNF-inhibitor treatment between 2004 and 2014 were identified from the National Register for Biologic Treatment in Finland, which is a longitudinal observational cohort study. Effectiveness was measured using the ACR and EULAR response criteria and by studying the proportion of patients reaching DAS28 remission. The patients' baseline characteristics were compared against the inclusion criteria of 27 RCTs. RESULTS: EULAR moderate and good treatment responses at 6 months were achieved by 69 and 40% of the users of the first TNF inhibitor, respectively. ACR20, ACR50 and ACR70 responses were reached by 48, 27 and 13%, respectively. DAS28 remission was reached by 47%. Only 7.6-44% of the patients would have been potentially eligible for the RCTs. The eligible patients had better treatment responses compared with the non-eligible patients. Different TNF inhibitors were mostly equipotent, but the usage of MTX co-therapy had a major influence on treatment response. CONCLUSION: Only a small proportion of patients would have been eligible for RCTs, and the efficacy of TNF inhibitors assessed in them cannot be generalized directly into Finnish routine health care.
引用
- Aaltonen KJ, Ylikylä S, Tuulikki Joensuu J, et al. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford). 2017. PMID: 28064209. doi:10.1093/rheumatology/kew467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。